We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




How Regulators of Fat Metabolism Work

By Biotechdaily staff writers
Posted on 25 Jul 2002
The hormone leptin has been found to specifically repress RNA levels and enzymatic activity of a gene that catalyzes the biosynthesis of monounsaturated fatty acids, causing fat to be metabolized for energy rather than being stored. More...
This finding and others were contained in an article published in the July 12, 2002, issue of Science.

Researchers at Rockefeller University (New York, NY, USA) found that when they crossed obese (ob/ob) mice that lack leptin with a strain called "asebia,” which carries mutations in the SCD-1 gene, the obese mice lost weight despite continuing to overeat. Leptin caused weight loss by reducing food intake and by increasing energy expenditure, while a deficiency of SCD-1 reduced obesity by increasing energy expenditure without affecting food intake at all.

Similar to leptin treatment, removal of SCD-1 markedly reduced the weight of the obese mice. At 16 weeks of age, weight was reduced by 29% in females and 34% in males. The reduced weight of these animals could be accounted for by a dramatic increase in energy expenditure. Removing SCD-1 completely corrected the effects of leptin deficiency on energy expenditure.

"The repression of SCD-1 accounts for a significant proportion, perhaps even all, of the effects of leptin on energy expenditure, explained Dr. Jeffrey Friedman of the laboratory of molecular genetics. "SCD-1 may act like a switch to control fat storage. When SCD-1 is ‘up,' the switch is flipped in the direction of storing fat, and when it's ‘down,' the switch is flipped in the direction of burning fat.”

Obese (leptin-deficient) mice also have massively fatty livers, which is corrected when the mice are given leptin. The lack of SCD-1 in the mutant mice also caused their livers to be normal and not fatty. "Inhibiting SCD-1 could be of potential use for reducing weight and for reducing fat content in liver, which is also an important clinical problem,” said Dr. Friedman. "Still, many more studies will be necessary to confirm that molecules that inhibit SCD-1 have an acceptable therapeutic index.”

In the current study investigators used DNA microarrays. These were evaluated with the help of a computer program that was able to sift through some 6,500 mouse genes contained in a single gene chip. The researchers sought genes that were specifically suppressed by leptin, and SCD-1 topped a final list of 36 genes.



Related Links:
Rockefeller University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.